Status:
UNKNOWN
Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder
Lead Sponsor:
China Medical University Hospital
Conditions:
Sjogren's Syndrome
Overactive Bladder Syndrome
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Overactive bladder is more prevalent among the Sjogren syndrome's population compare to the general population. Both anti-muscarinic agent and beta-3 agonist are recommended as second line treatment f...
Detailed Description
Overactive bladder(OAB) is a syndrome characterized by the presence of frequency, urgency, nocturia, and with or without urgency urinary incontinence. The reported prevalence of overactive bladder was...
Eligibility Criteria
Inclusion
- Diagnosis of Sjogren's syndrome AND
- Clinical diagnosis of OAB
Exclusion
- Congenital or acquired anatomic abnormalities of the genitourinary tract,
- Uncontrolled severe hypertension \>180 mmHg
- Cannot cooperate for voiding diary documentation
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04909255
Start Date
March 23 2021
End Date
August 15 2022
Last Update
August 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 40421